医药行业：405家医药上市公司2025Q3同比2024Q3的销售收入、归母净利润、扣非归母净利润总额增速分别为-0.1%、3.0%、-3.9%。2025年Q3收入增长同比最快的三个细分领域依次为CXO、科研服务、制药；扣非净利润增长同比最快的三个细分领域依次为科研服务、CXO、药店。创新药：创新药现阶段已然成为医药板块的重要主线，为此我们选择了A股58家创新药企业作为国内创新药企业样本，以衡量中国...
Source Link医药行业：405家医药上市公司2025Q3同比2024Q3的销售收入、归母净利润、扣非归母净利润总额增速分别为-0.1%、3.0%、-3.9%。2025年Q3收入增长同比最快的三个细分领域依次为CXO、科研服务、制药；扣非净利润增长同比最快的三个细分领域依次为科研服务、CXO、药店。创新药：创新药现阶段已然成为医药板块的重要主线，为此我们选择了A股58家创新药企业作为国内创新药企业样本，以衡量中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.